ロード中...
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Plasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of advanced non–small-cell lung cancer (NSCLC); however, early response assessment using plasma ctDNA has yet to be well characterized. MATERIALS AND METHODS: Patients with advanced EGFR-mutant NSCLC across three phase I NCI osi...
保存先:
| 出版年: | JCO Precis Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8232122/ https://ncbi.nlm.nih.gov/pubmed/34250387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00419 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|